$RAPP

Form 144: Morgan Stanley Smith Barney (NASDAQ: RAPP) lists 360-share sale

Morgan Stanley Smith Barney LLC has filed a Form 144 indicating a proposed sale of 360 shares of Rapport Therapeutics, Inc. (NASDAQ: RAPP) common stock. The filing also disclosed 10b5-1 sales of 10,115 shares on March 25, 2026, for gross proceeds of $303,354.24. As of April 8, 2026, Rapport Therapeutics has 47,792,943 shares outstanding.

Original reporting
Published Apr 9, 2026, 5:40 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 9, 2026, 6:00 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$RAPP
Neutral
medium confidence
Mentioned
$RAPP
alphai data visualization · based on Stock Titan
Decision brief

The 30-second read

$RAPPNeutralLow
01

Why it matters

The sale by Morgan Stanley Smith Barney is a standard liquidity event and does not reflect on the company's fundamentals.

02

Market read

The insider sale has limited immediate impact on the stock's trading dynamics but warrants monitoring for future insider activity.

03

What to watch

Recent company performance, upcoming catalysts, and broader market conditions could overshadow this insider activity.

Timing: short-term

Background

Rapport Therapeutics is a NASDAQ-listed biotech company with ongoing research and development activities.

Company-level read

Ticker impact

$RAPPNeutralMedium confidence
Context

The filing indicates a significant insider sale of Rapport Therapeutics shares, which could suggest insider sentiment or liquidity considerations.

Expected impact

Minimal immediate impact; potential slight downward pressure if the sale signals insider caution.

Evidence & confidence

The sale volume is relatively small compared to the total shares outstanding (~47.8 million), suggesting limited impact. Insider sales can be routine and do not always indicate negative sentiment.

Market effects

Limited; the sale does not indicate sector-wide concerns.

Negligible; insider sales are company-specific.

Negligible; no global implications.

Counterpoint

The insider sale might be routine diversification or personal liquidity needs, not necessarily negative for the company.

Key entities

  • Rapport Therapeutics

    A biotechnology company focused on neurological disorders.

  • Morgan Stanley Smith Barney

    A major financial services firm involved in the sale.

Related articles

$RAPPMed

Rapport Therapeutics, Inc. (RAPP): Results of Operations and Financial Condition

Rapport Therapeutics, Inc. (RAPP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 rapp-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update RAP-219 Phase 3 program in focal onset seizures initiated, with FOCUS 1 and FOCUS 2 trials enrolling patients RAP-219 Phase 2 trial in b

$BKRMed

Baker Hughes extends long-term service deal for Nigeria LNG Train 7

Baker Hughes said it won a 13-year lifecycle services deal with Nigeria LNG for turbomachinery at NLNG’s Train 7 expansion on Bonny Island. The scope covers heavy-duty gas turbines, centrifugal compressors, remote monitoring via Baker Hughes’ digital platform, and local support. Train 7 is expected to raise capacity from 22 to 30 MMtpa.

$BKRMed

Baker Hughes wins subsea systems contract for Angola's Greater PAJ field

Baker Hughes said it won a contract from Azule Energy to supply subsea production systems for the Greater PAJ ultra-deepwater project offshore Angola. Scope includes horizontal subsea trees, control modules, workover control systems and related equipment plus installation and support. Greater PAJ is expected to start producing in 2029 via an FPSO processing up to 95,000 bpd, with deliveries starting in 2027.

$WENMed

57-year-old Burger chain closed 28 restaurants, 100s more coming

Wendy’s (WEN) said it closed 28 restaurants and expects to close 5% to 6% of U.S. units (about 289 to 358) in 1H 2026, with possible additional selective closures. The company reported 2Q FY2026 systemwide sales down 6.5% YoY, U.S. systemwide down 8.2%, and U.S. same-restaurant sales down 7%. Wendy’s launched a turnaround plan and withdrew its 2026 outlook.

$ACIMed

Albertsons recalls ready-to-eat items in multiple states amid salmonella-linked jalapeño investigation

Albertsons Companies said it is voluntarily recalling four ready-to-eat products containing jalapeños supplied by Taylor Farms, including items sold at Randalls in Texas. The recall followed a supplier recall tied to an ongoing federal investigation and an FDA probe of a Salmonella Javiana outbreak. FDA reported 345 illnesses in 27 states, 36 hospitalizations, no deaths.